BIOMAT Database Logo BIOMAT Database Logo

Preparation of chitosan-based nanoparticles for delivery of low molecular weight heparin. 2011

Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
School of Pharmaceutical Sciences, Shandong University, Jinan 250012 China.

The chitosan nanoparticles (CSNPs) loading with low molecular weight heparin (LMWH) was prepared by ionic gelatin process of chitosan (CS) and sodium tripolyphosphate (TPP) and the preparation process was optimized by a central composite design (CCD). Encapsulation efficiency (96.98%), loading efficiency (30.76%), average diameter (814 nm) and zeta potential (+0.86 mV) were achieved for the optimal nanoparticle (NP) formulation, and the release behavior of drug from CSNPs in vitro fitted Weibull kinetics model. The relative bioavailability of oral administration in rats of LMWH loaded CSNPs to LMWH solution was 517%. The results showed that CCD may well predict desired in vitro characterization of LMWH CSNPs, and CSNPs can significantly enhance the oral absorption of LMWH in rats.

UI MeSH Term Description Entries
D008297 Male Males
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015951 Factor Xa Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors. Autoprothrombin C,Coagulation Factor Xa,Factor X, Activated,Thrombokinase,Activated Factor X,Blood Coagulation Factor X, Activated,Factor 10A,Factor Ten A,Factor Xa, Coagulation
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Preparation and optimization of N-trimethyl-O-carboxymethyl chitosan nanoparticles for delivery of low-molecular-weight heparin.
January 2016, Pharmaceutical development and technology,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Low molecular weight heparin gels, based on nanoparticles, for topical delivery.
April 2012, International journal of pharmaceutics,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Low molecular weight chitosan-cyanocobalamin nanoparticles for controlled delivery of ciprofloxacin: Preparation and evaluation.
April 2021, International journal of biological macromolecules,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
pH-responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation.
January 2016, Drug delivery,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Microneedle based transcutaneous delivery of low molecular weight heparin.
May 2021, Pakistan journal of pharmaceutical sciences,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel.
January 2014, International journal of nanomedicine,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Buccal delivery of low molecular weight heparin by cationic polymethacrylate nanoparticles.
December 2016, International journal of pharmaceutics,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Preparation and evaluation of a novel oral delivery system for low molecular weight heparin.
January 2016, International journal of pharmaceutical investigation,
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary Delivery of Tobramycin for Cystic Fibrosis.
March 2018, Pharmaceuticals (Basel, Switzerland),
Juan Wang, and Haining Tan, and Aihua Yu, and Peixue Ling, and Hongxiang Lou, and Guangxi Zhai, and Jun Wu
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
January 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
Copied contents to your clipboard!